MTAP and urothelial neoplasm: In a previous study evaluating more than 13,000 cancers from 149 different tumor types by MTAP IHC, we identified several MTAP-deficient tumor types including neuroendocrine neoplasms (up to 80% MTAP-deficient), Hodgkin lymphoma (50.0% MTAP-deficient), mesothelioma (up to 37% MTAP-deficient), gastro-intestinal adenocarcinoma (up to 41% MTAP-deficient), urothelial neoplasms (up to 37% MTAP-deficient), and squamous cell carcinomas (up to 38% MTAP-deficient).